Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 18:00:00 03/07/2024 BST			5-day change	1st Jan Change
153.1 ^USD	-0.71%		-2.42%	+58.78%

06-26	Monetary policy is getting even more confusing
06-26	Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172	MT

Sarepta Therapeutics, Inc. Provides EXONDYS 51 Revenue Guidance for the Fourth Quarter 2017, Full Year 2017 and Full Year 2018

January 08, 2018 at 06:44 pm

Sarepta Therapeutics, Inc. provided EXONDYS 51 revenue guidance for the fourth quarter 2017, full year 2017 and full year 2018. The company expects revenue for the fourth quarter will total $57.3 million. The company expects revenue of $154.6 million for the full-year of 2017. EXONDYS 51 revenue guidance for 2018 will be in the range of $295 million - $305 million.

Latest news about Sarepta Therapeutics, Inc.

Monetary policy is getting even more confusing	06-26
Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172	06-26	MT
Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172	06-26	MT
ANALYST RECOMMENDATIONS : Accenture, Chipotle, Rivian, Walmart, Humana...	06-26
Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating	06-24	MT
Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating	06-24	MT
Key week for monetary policy	06-24
BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating	06-24	MT
ANALYST RECOMMENDATIONS : Accenture, Walgreens Boots Alliance, Ge Vernova, Pepsico, Britvic...	06-24
Health Care Stocks Boosted By Duchenne MS Drug -- Health Care Roundup	06-21	DJ
Sector Update: Health Care Stocks Gain in Late Afternoon	06-21	MT
S&P, Nasdaq edge down as Nvidia declines for second day	06-21	RE
Top Midday Gainers	06-21	MT
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	06-21	MT
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says	06-21	MT
S&P 500, Nasdaq lower as semiconductor shares weigh	06-21	RE
Barclays Adjusts Price Target on Sarepta Therapeutics to $226 From $185, Maintains Overweight Rating	06-21	MT
Sarepta surges as investors cheer expanded use of gene therapy	06-21	RE
Tech overload on Wall Street	06-21
Wall Street set for muted open as investors await business survey data	06-21	RE
Sector Update: Health Care Stocks Steady Premarket Friday	06-21	MT
Sector Update: Health Care	06-21	MT
Nvidia Slide Stifles US Equity Futures Pre-Bell	06-21	MT
BofA Securities Adjusts Sarepta Therapeutics Price Target to $213 From $166, Maintains Buy Rating	06-21	MT
Oppenheimer Adjusts Sarepta Therapeutics Price Target to $215 From $180, Maintains Outperform Rating	06-21	MT

Chart Sarepta Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

Sector

Biotechnology & Medical Research

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sarepta Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

153.1 USD

Average target price

201 USD

Spread / Average Target

+31.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SAREPTA THERAPEUTICS, INC.	+58.78%	14.47B
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	121B
REGENERON PHARMACEUTICALS, INC.	+16.60%	110B
ARGENX SE	+17.73%	25.93B
BIONTECH SE	-24.33%	19.27B
GENMAB A/S	-19.35%	16.01B
BEIGENE, LTD.	-17.95%	15.66B
WUXI APPTEC CO., LTD.	-48.32%	14.89B
NEUROCRINE BIOSCIENCES, INC.	+4.91%	13.91B
INSMED INCORPORATED	+100.06%	10B

Bio Therapeutic Drugs